EUVIMEDEUVIMED entdecken
Crossref

Bayesian Predictive Probability Based on a Bivariate Index Vector for Single‐Arm Phase II Study With Binary Efficacy and Safety Endpoints

Takuya Yoshimoto iD, Satoru Shinoda, Kouji Yamamoto, Kouji Tahata

Pharmaceutical Statistics · 2025

DOI: 10.1002/pst.2431 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Statistics, 2025. Verfasst von Takuya Yoshimoto und 3 weiteren Autor:innen. Beteiligte Einrichtung: Biometrics Department, Chugai Pharmaceutical Co. Ltd, Chuo-ku, Tokyo, Japan. Hauptthemen laut MEDLINE: Clinical Trials, Phase II as Topic, Research Design, Endpoint Determination, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In oncology, Phase II studies are crucial for clinical development plans as such studies identify potent agents with sufficient activity to continue development in the subsequent Phase III trials. Traditionally, Phase II studies are single‐arm studies, with the primary endpoint being short‐term treatment efficacy. However, drug safety is also an important consideration. In the context of such multiple‐outcome designs, predictive probability‐based Bayesian monitoring strategies have been developed to assess whether a clinical trial will provide enough evidence to continue with a Phase III study at the scheduled end of the trial. Therefore, we propose a new simple index vector to summarize the results that cannot be captured by existing strategies. Specifically, we define the worst and most promising situations for the potential effect of a treatment, then use the proposed index vector to measure the deviation between the two situations. Finally, simulation studies are performed to evaluate the operating characteristics of the design. The obtained results demonstrate that the proposed method makes appropriate interim go/no‐go decisions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials, Phase II as TopicResearch DesignEndpoint DeterminationAntineoplastic AgentsBayes TheoremHumansProbabilityComputer SimulationModels, Statistical

Stichwörter der Autor:innen

Bayesian monitoringefficacy and toxicity endpointsindex vectorpredictive probabilitysingle‐arm Phase II study

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Biometrics Department, Chugai Pharmaceutical Co. Ltd, Chuo-ku, Tokyo, Japan.
  • Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, Kanagawa, Japan.
  • Department of Information Sciences, Faculty of Science and Technology, Tokyo University of Science, Chiba, Japan.

ORCID-Profile: Takuya Yoshimoto

Zitieren

APA

Yoshimoto, T., Shinoda, S., Yamamoto, K., & Tahata, K. (2025). Bayesian Predictive Probability Based on a Bivariate Index Vector for Single‐Arm Phase II Study With Binary Efficacy and Safety Endpoints. Pharmaceutical Statistics. https://doi.org/10.1002/pst.2431

Vancouver

Yoshimoto T, Shinoda S, Yamamoto K, Tahata K. Bayesian Predictive Probability Based on a Bivariate Index Vector for Single‐Arm Phase II Study With Binary Efficacy and Safety Endpoints. Pharmaceutical Statistics. 2025. doi:10.1002/pst.2431

BibTeX
@article{Yoshimoto2025,
  author = {Yoshimoto, Takuya and Shinoda, Satoru and Yamamoto, Kouji and Tahata, Kouji},
  title = {Bayesian Predictive Probability Based on a Bivariate Index Vector for Single‐Arm Phase II Study With Binary Efficacy and Safety Endpoints},
  journal = {Pharmaceutical Statistics},
  year = {2025},
  doi = {10.1002/pst.2431}
}
Kostenlos starten →